Source ARM Organovo Collaborates With MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney DiseaseMay 30, 2019 – (Organovo) – This multi-organizational effort integrates Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise. The collaboration has been made possible through generous
Encouraging Clinical Data Generated from Ongoing Proof-of-Concept Study Conducted by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget); Enrollment Expected to Complete in the First Half of 2020 Leverages Orchard’s Expertise in Treating Neurometabolic Diseases Using its Investigational Autologous Hematopoietic Stem Cell Gene Therapy Builds Upon Orchard / SR-Tiget Partnership to Develop Novel Gene Therapy Candidates Orchard Therapeutics, Fondazione
Universities of Birmingham and Oxford brings us a step closer to developing targeted therapies for inflammatory diseases. The research team shows, for the first time, that different types of fibroblasts – the most common cells of connective tissue in animals – are organised in different layers in the joint and are responsible for two very
Dr. Robert A. Preti, theCEO and President of Hitachi Chemical Advanced Therapeutics Solutions (HCATS), was recently interviewed by Global Business Reports (GBR) for their 2019 US Biopharmaceuticals report. The GBR report covers a range of topics, such as the state of the biopharma industry, new developments in biopharmaceutical manufacturing, the investment climate for cell and gene
A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumour attack. Since then CAR T approaches (one of several strategies collectively known as “adoptive T cell transfer”) have made headlines
Athersys announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the
Source European Commission Atherosclerosis is a common, potentially serious condition caused by a build-up of fatty material in the lining of the artery walls. It can lead to coronary artery disease, stroke or kidney problems, and existing treatments tend to be only short-term fixes. In response to this public health challenge, EU-funded project THE GRAIL
In light of additional data from ongoing trials of onasemnogene abeparvovec (Zolgensma®, Novartis/AveXis), as well as the treatment’s final FDA label and just-announced launch price, the Institute for Clinical and Economic Review (ICER) today published an addendum to its Final Evidence Report on treatments for spinal muscular atrophy (SMA). Since the publication of ICER’s Final Evidence Report on
Source STAT he Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most expensive drug in the world. Known as Zolgensma, the gene therapy treats children under 2 years of age with spinal muscular atrophy, an
Source ARM Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s HElix Endocardial Delivery System Improved in Ejection Fraction and NYHA ClassMay 23, 2019 – (BioCardia) – At 12 months, patients with Helix-delivered cell therapy experienced a 7.33 percent imprvement in ejection fraction at 12 months compared to the control group. Helix patients
